Enobosarm
- Generic Name
- Enobosarm
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F3N3O3
- CAS Number
- 841205-47-8
- Unique Ingredient Identifier
- O3571H3R8N
- Background
Enobosarm has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
- Conditions
- Muscle LossObesity
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06282458
- Locations
- 🇺🇸
SKY Integrative Medical Center, Ridgeland, Mississippi, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Palm Research Center, Las Vegas, Nevada, United States
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05065411
- Locations
- 🇺🇸
Lakes Research, Miami Lakes, Florida, United States
🇺🇸UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Banner MDACC, Gilbert, Arizona, United States
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04869943
- Locations
- 🇺🇸
Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
- Locations
- 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸William Beaumont Hospital Urology Research, Royal Oak, Michigan, United States
🇺🇸Aventiv Research, Columbus, Ohio, United States
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
- Conditions
- Stress Urinary Incontinence
- Interventions
- Drug: Matching Placebo
- Locations
- 🇺🇸
Urology Associates Research, Englewood, Colorado, United States
🇺🇸Regional Urology, Shreveport, Louisiana, United States
🇺🇸Beyer Research, Kalamazoo, Michigan, United States
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Havah Therapeutics Pty Ltd
- Target Recruit Count
- 9
- Registration Number
- NCT03264651
- Locations
- 🇦🇺
Wellend Health, Toorak Gardens, South Australia, Australia
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- GTx
- Target Recruit Count
- 491
- Registration Number
- NCT03241342
- Locations
- 🇺🇸
William Beaumont Hospital Urology Research, Royal Oak, Michigan, United States
🇺🇸Circuit Clinical, West Seneca, New York, United States
🇺🇸Alliance Urology Specialist PA, Greensboro, North Carolina, United States
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
- Conditions
- Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu NegativeMetastatic Triple-Negative Breast CarcinomaProgesterone Receptor NegativeStage IV Breast Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT02971761
- Locations
- 🇺🇸
City of Hope West Covina, West Covina, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Mission Hills, Mission Hills, California, United States
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- GTx
- Target Recruit Count
- 19
- Registration Number
- NCT02658448
- Locations
- 🇺🇸
Penn Center for Continence and Pelvic Health, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- GTx
- Target Recruit Count
- 136
- Registration Number
- NCT02463032
- Locations
- 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The West Clinic, PC, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.